Tumor Volume Equipment
-
Manufactured by BridgeBio Pharma, Inc.based in USA
designed to target glutathione peroxidase 4 (GPX4) with the hope of providing an effective new therapy for patients with difficult-to-treat tumors. Our approach has demonstrated monotherapy activity, reducing tumor volume in a mouse xenograft model of renal cell carcinoma. Recent high profile publications provide preclinical in vivo ...
-
Manufactured by Computerized Imaging Reference Systems, Inc (CIRS)based in USA
Stereotactic Radiosurgery (SRS) necessitates a high degree of accuracy in target localization and dose delivery. Small errors can result in significant under treatment of portions of the tumor volume and overdose of nearby normal tissues. The CIRS Stereotactic End-to-End Verification Phantom (STEEV) provides a means to check all necessary ...
-
by CohBar, Inc.based in USA
Our CB5046 Analogs inhibit the CXCR4 receptor, which is overexpressed in ~75% of human tumors. In addition to potential applications in oncology, CXCR4 inhibitors may also have utility in certain genetic diseases due to their ability to mobilize stem ...
-
Manufactured by Biopticon Corporationbased in USA
a tumor in the recorded image and calculate the volume or area. When interfaced to TumorManager 2 this leads to a simple but robust, data-verified measurement system that offers speed, accuracy and flexibility. TumorImager 2 can be quickly converted between a “supermarket-style” hand-held tumor scanner and hands-free scanner ...
-
Manufactured by AC BioScience SAbased in SWITZERLAND
Our product is a new-generation CAP6 that shows great promise as a highly effective treatment for lung cancer (NSCLC). Lung cancer is one of the most widely prevalent cancers, and one of the most difficult to treat. Eighty-one percent of patients treated for lung cancer die within five ...
-
Manufactured by Elpisciencebased in CHINA
ES002’s dual ATP-adenosine mechanism is a potentially powerful TME regulator and transformative cancer immunotherapy. In preclinical studies ES002 demonstrated significant single agent anti-tumor activity as well as an excellent tolerability profile. ES002 has also shown superior enzymatic inhibition and binding ...
-
based in USA
STAR-LLD is in development in two continuous delivery systems: subcutaneous and transdermal. STAR-LLD is in development for new multiple myeloma indications for lenalidomide and achievement of superiority versus oral lenalidomide in maintenance treatment of multiple myeloma. The STAR-LLD delivery system is expected to provide significant reductions in discontinuations and treatment abandonment by ...
-
based in USA
Vitanova Biomedical’s Cancer Therapy Technology Platform is Called Light-Activated Intracellular Acidosis (LAIA). Vitanova Biomedical (VNB) has developed a proprietary energy-based technique to elicit cancer-specific intracellular acidosis. The foundation of VNB’s core technology combines three proven principles accepted in today’s cancer therapeutics: Intracellular acidosis ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you